BALPHARMA105.50

Bal Pharma Limited

· Pharma & Health
₹ CrorePeersALPAKREBSBIONATCAPSUQVINEETLABNECLIFEAAREYDRUGSBIOFILCHEMMANGALAMMcap ₹168 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt139.6150.4159.5159.5
Net Debt128.7146.2155.1155.1
Total Debt/Equity2.021.941.941.94
Net Debt/Equity1.861.891.891.89
Total Debt/EBITDA4.435.095.005.00
Net Debt/EBITDA4.084.954.864.59
Interest Coverage (EBIT/Interest)1.411.171.241.24
Total Debt/Total Capital %66.8566.0265.9865.98
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.